1/15/2014 2:52:06 PM
VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. 15, 2014) - Sirona Biochem Corp. (TSX VENTURE:SBM)(OTCQX:SRBCF) and Cincinnati Children's Hospital Medical Center announce the formalization of a license agreement of Cincinnati Children's patented synthetic vernix technology.
Sirona Biochem plans to create an anti-aging skin care treatment that combines their patented cell preservation glycoprotein with Cincinnati Children's technology.
Sirona will lead the development, with support from Cincinnati Children's, of the anti-aging cream incorporating the proprietary technologies of each organization. The resulting new anti-aging product will be patented with the goal of licensing the new technology to a global leader in the cosmetic and consumer packaged good marketplaces.
It is expected by both Sirona and Cincinnati Children's that new patents and applications (cosmetic and therapeutic) for this combined technology may be discovered and the collaboration is structured to support the goal of future commercial revenue from multiple sources.
"We are proud to be working in partnership with Cincinnati Children's Hospital Medical Center, a world leader in patient care and breakthrough research," said Neil Belenkie, CEO of Sirona Biochem. "Our shared goal is to create an anti-aging skin treatment that presents unparalleled efficacy and commercial opportunity for the predicted $300 billion dollar anti-aging global market."
"We are excited to formalize this agreement with Sirona Biochem and look forward to continuing to work together," said Niki Robinson, PhD, assistant vice president of Cincinnati Children's Center for Technology Commercialization.
About Sirona Biochem
Sirona Biochem is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France. The company specializes in the stabilization of carbohydrate molecules, with the goal of improving compounds' efficacy and safety. Sirona Biochem's compounds are patented as new chemical entities for maximum commercial protection and revenue potential. Newly developed compounds are licensed to leading companies around the world in return for licensing and milestone fees and ongoing royalty payments. TFChem, Sirona Biochem's wholly-owned French laboratory is a recipient of multiple French national scientific awards and a European Union and French government grant. For more information visit www.sironabiochem.com.
About Cincinnati Children's Hospital Medical Center
Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S. News and World Report's 2013 Best Children's Hospitals ranking. It is ranked #1 for cancer and in the top 10 for nine of 10 pediatric specialties. Cincinnati Children's, a non-profit organization, is one of the top three recipients of pediatric research grants from the National Institutes of Health, and a research and teaching affiliate of the University of Cincinnati College of Medicine. The medical center is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education and innovation. Additional information can be found at www.cincinnatichildrens.org . Connect on the Cincinnati Children's blog, via Facebook and on Twitter.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Sirona Biochem cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. Forward-looking statements are only predictions based upon current expectations and involve known and unknown risks and uncertainties. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of release of the relevant information, unless explicitly stated otherwise. Actual results, performance or achievement could differ materially from those expressed in, or implied by, Sirona Biochem's forward-looking statements due to the risks and uncertainties inherent in Sirona Biochem's business including, without limitation, statements about: the progress and timing of its clinical trials; difficulties or delays in development, testing, obtaining regulatory approval, producing and marketing its products; unexpected adverse side effects or inadequate therapeutic efficacy of its products that could delay or prevent product development or commercialization; the scope and validity of patent protection for its products; competition from other pharmaceutical or biotechnology companies; and its ability to obtain additional financing to support its operations. Sirona Biochem does not assume any obligation to update any forward-looking statements except as required by law.
Help employers find you! Check out all the jobs and post your resume.
comments powered by